進行性骨化性線維異形成症市場：オファリング別、投与経路別、エンドユーザー別-2025～2030年の世界予測

進行性骨化性線維異形成症市場は、2023年に4億7,046万米ドルと評価され、2024年には4億9,459万米ドルに達すると予測され、CAGR 5.30%で成長し、2030年には6億7,565万米ドルに達すると予測されています。

進行性骨化性線維異形成症（FOP）は、超希少な遺伝性疾患で、軟部組織が徐々に骨化し、身体の可動性が著しく制限され、身体機能に不可欠な合併症を引き起こします。FOPの市場範囲は、その希少性から高度に専門化されているが、患者のQOLに大きな影響を与えるため、医療研究とイノベーションの観点からは極めて重要です。予防薬や治療の開発の必要性は、現在利用可能な効果的な治療オプションの欠如によって強調されており、人道的と経済的なインセンティブが強調されています。用途は、新薬開発、遺伝子治療、骨生物学研究から、運動機能障害に特化した補助技術や義肢まで多岐にわたります。最終用途としては、医療プロバイダー、研究機関、製薬会社が主要対象で、1次調査と2次調査として補装具メーカーがあります。

市場成長の原動力は、政府や民間からの資金提供の増加、遺伝学の進歩、医療専門家の意識の高まりであり、バイオテクノロジー企業や学術機関の協力関係を後押ししています。遺伝子編集のための先進的CRISPR技術の活用や、異所性骨化に関与する特定の経路を標的とする生物製剤の開発には潜在的な機会が存在します。このような機会を捉えるための提言としては、リソースを共有するための戦略的パートナーシップの形成や、初期段階のバイオ医薬品ベンチャーへの投資などがあります。しかし、研究や臨床検査にかかる高いコストと時間、研究の実現可能性を複雑にする小さな患者集団、規制上のハードルなどの限界は、依然として手ごわい課題です。

イノベーションの展望としては、新たな分子経路の探索、AIや機械学習による診断ツールの改善、個別化医療アプローチを強化するための患者主導型データセットの活用などが挙げられます。同市場はダイナミックでニッチな性質が特徴で、俊敏性と持続的な研究開発投資が求められます。イノベーションの取り組みを患者中心のケアモデルと整合させ、新たな技術を活用し、利害関係者間の協力的なエコシステムを育成することで、希少疾患治療ソリューションの進化に歩調を合わせ、事業の成長を最大化することができます。

市場力学：急速に進化する進行性骨化性線維異形成症市場の主要市場洞察を公開

進行性骨化性線維異形成症市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネス機会の獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 進行性骨化性線維異形成症疾患の罹患率の増加
  • 希少疾患や遺伝性疾患に対する医療専門家や一般市民の意識の高まり
• 市場抑制要因
  • 進行性骨化性線維異形成症治療の開発コストの高さ
• 市場機会
  • 新規進行性骨化性線維異形成症治療法開発のための研究開発活動の活発化
  • 希少疾患に対する政府の資金援助と認可の利用可能性
• 市場課題
  • 進行性骨化性線維異形成症の認知度の低さ

ポーターのファイブフォース：進行性骨化性線維異形成症市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、進行性骨化性線維異形成症市場の競合情勢を理解するための重要なツールです。ポーターのファイブフォースフレームワークは、企業の競合を評価し、戦略的機会を探るための明確な手法を記載しています。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これら洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：進行性骨化性線維異形成症市場における外部からの影響の把握

外部マクロ環境要因は、進行性骨化性線維異形成症市場の業績力学を形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を記載しています。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析：進行性骨化性線維異形成症市場における競合情勢の把握

進行性骨化性線維異形成症市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、セグメント化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的な意思決定を行うために必要な知見を得ることができます。

FPNVポジショニングマトリックス：進行性骨化性線維異形成症市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、進行性骨化性線維異形成症市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨：進行性骨化性線維異形成症市場における成功への道筋を描く

進行性骨化性線維異形成症市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネス機会を活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目セグメントを網羅した市場の包括的な分析を提供しています。

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力を評価します。

2.市場の開拓度：新興市場における成長機会を特定し、既存セグメントにおける拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを記載しています。

3.市場の多様化：最近の製品発売、未開拓の地域、産業の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発とイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています。

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、地域はどこか？

3.市場を形成する主要技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 進行性骨化性線維異形成症疾患の発生率増加
    • 希少疾患や遺伝性疾患に対する医療従事者や一般市民の意識の高まり
  • 抑制要因
    • 進行性骨化性線維異形成症治療の開発コストが高い
  • 機会
    • 新しい治療法を開発するための研究開発活動の増加
    • 希少疾患に対する政府の資金援助と承認の有無
  • 課題
    • 進行性骨化性線維異形成症の認知度が低い
• 市場セグメンテーション分析
  • オファリング：FOPにおける異所性骨化の進行を抑えるパロバロテンの需要増加
  • エンドユーザー：FOPの診断、治療、継続的な管理のために病院で進行性骨化性線維異形成症薬剤が頻繁に使用されている
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治
  • 経済
  • 社会
  • 技術
  • 法律
  • 環境

第6章 進行性骨化性線維異形成症市場：オファリング別

• イントロダクション
• 薬剤タイプ
  • 抗炎症薬
  • ビスフォスフォネート
  • コルチコステロイド
  • パロバロテネ
• 治療
  • 薬剤治療
  • 作業療法
  • 手術

第7章 進行性骨化性線維異形成症市場：投与経路別

• イントロダクション
• 経口
• 非経口
• 局所

第8章 進行性骨化性線維異形成症市場：エンドユーザー別

• イントロダクション
• 病院
• 研究機関
• 専門クリニック

第9章 南北アメリカの進行性骨化性線維異形成症市場

• イントロダクション
• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋の進行性骨化性線維異形成症市場

• イントロダクション
• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの進行性骨化性線維異形成症市場

• イントロダクション
• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析、2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析
  • FDAがIpsenの進行性骨化性線維異形成症治療を承認
• 戦略分析と提言

企業一覧

• Abbvie Inc.
• Accord Healthcare, Inc
• Amgen Inc.
• BioCryst Pharmaceuticals, Inc.
• bioMerieux S.A.
• Blueprint Medicines Corporation
• Boehringer Ingelheim International GmbH
• Daiichi Sankyo Company, Limited
• Incyte Corporation
• Ipsen Pharma
• Merck & Co Inc.
• Novartis AG
• Pfizer, Inc.
• Regeneron Pharmaceuticals, Inc.
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceuticals Industries Ltd.
• Thermo Fisher Scientific, Inc.

LIST OF FIGURES

• FIGURE 1. FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET RESEARCH PROCESS
• FIGURE 2. FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET DYNAMICS
• TABLE 7. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ANTI-INFLAMMATORY MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY BISPHOSPHONATES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY PALOVAROTENE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY MEDICATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OCCUPATIONAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. AMERICAS FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 30. AMERICAS FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 31. AMERICAS FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 32. AMERICAS FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 33. ARGENTINA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 34. ARGENTINA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 35. ARGENTINA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 36. ARGENTINA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 37. ARGENTINA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 38. BRAZIL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 39. BRAZIL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 40. BRAZIL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 41. BRAZIL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 42. BRAZIL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 43. CANADA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 44. CANADA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 45. CANADA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 46. CANADA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 47. CANADA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 48. MEXICO FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 49. MEXICO FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 50. MEXICO FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 51. MEXICO FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 52. MEXICO FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 53. UNITED STATES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 54. UNITED STATES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 55. UNITED STATES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 56. UNITED STATES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 57. UNITED STATES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 58. UNITED STATES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 59. ASIA-PACIFIC FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 60. ASIA-PACIFIC FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 61. ASIA-PACIFIC FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 62. ASIA-PACIFIC FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 63. ASIA-PACIFIC FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 64. ASIA-PACIFIC FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 65. AUSTRALIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 66. AUSTRALIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 67. AUSTRALIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 68. AUSTRALIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 69. AUSTRALIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 70. CHINA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 71. CHINA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 72. CHINA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 73. CHINA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 74. CHINA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 75. INDIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 76. INDIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 77. INDIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 78. INDIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 79. INDIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 80. INDONESIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 81. INDONESIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 82. INDONESIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 83. INDONESIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 84. INDONESIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 85. JAPAN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 86. JAPAN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 87. JAPAN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 88. JAPAN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 89. JAPAN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 90. MALAYSIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 91. MALAYSIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 92. MALAYSIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 93. MALAYSIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 94. MALAYSIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 95. PHILIPPINES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 96. PHILIPPINES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 97. PHILIPPINES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 98. PHILIPPINES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 99. PHILIPPINES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 100. SINGAPORE FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 101. SINGAPORE FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 102. SINGAPORE FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 103. SINGAPORE FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 104. SINGAPORE FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 105. SOUTH KOREA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 106. SOUTH KOREA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 107. SOUTH KOREA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 108. SOUTH KOREA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 109. SOUTH KOREA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 110. TAIWAN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 111. TAIWAN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 112. TAIWAN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 113. TAIWAN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 114. TAIWAN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 115. THAILAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 116. THAILAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 117. THAILAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 118. THAILAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 119. THAILAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 120. VIETNAM FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 121. VIETNAM FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 122. VIETNAM FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 123. VIETNAM FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 124. VIETNAM FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 125. EUROPE, MIDDLE EAST & AFRICA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 126. EUROPE, MIDDLE EAST & AFRICA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 127. EUROPE, MIDDLE EAST & AFRICA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 128. EUROPE, MIDDLE EAST & AFRICA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 129. EUROPE, MIDDLE EAST & AFRICA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 130. EUROPE, MIDDLE EAST & AFRICA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 131. DENMARK FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 132. DENMARK FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 133. DENMARK FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 134. DENMARK FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 135. DENMARK FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 136. EGYPT FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 137. EGYPT FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 138. EGYPT FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 139. EGYPT FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 140. EGYPT FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 141. FINLAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 142. FINLAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 143. FINLAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 144. FINLAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 145. FINLAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 146. FRANCE FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 147. FRANCE FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 148. FRANCE FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 149. FRANCE FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 150. FRANCE FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 151. GERMANY FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 152. GERMANY FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 153. GERMANY FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 154. GERMANY FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 155. GERMANY FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 156. ISRAEL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 157. ISRAEL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 158. ISRAEL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 159. ISRAEL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 160. ISRAEL FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 161. ITALY FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 162. ITALY FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 163. ITALY FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 164. ITALY FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 165. ITALY FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 166. NETHERLANDS FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 167. NETHERLANDS FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 168. NETHERLANDS FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 169. NETHERLANDS FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 170. NETHERLANDS FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 171. NIGERIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 172. NIGERIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 173. NIGERIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 174. NIGERIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 175. NIGERIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 176. NORWAY FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 177. NORWAY FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 178. NORWAY FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 179. NORWAY FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 180. NORWAY FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 181. POLAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 182. POLAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 183. POLAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 184. POLAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 185. POLAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 186. QATAR FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 187. QATAR FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 188. QATAR FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 189. QATAR FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 190. QATAR FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 191. RUSSIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 192. RUSSIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 193. RUSSIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 194. RUSSIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 195. RUSSIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 196. SAUDI ARABIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 197. SAUDI ARABIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 198. SAUDI ARABIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 199. SAUDI ARABIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 200. SAUDI ARABIA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 201. SOUTH AFRICA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 202. SOUTH AFRICA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 203. SOUTH AFRICA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 204. SOUTH AFRICA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 205. SOUTH AFRICA FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 206. SPAIN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 207. SPAIN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 208. SPAIN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 209. SPAIN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 210. SPAIN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 211. SWEDEN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 212. SWEDEN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 213. SWEDEN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 214. SWEDEN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 215. SWEDEN FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 216. SWITZERLAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 217. SWITZERLAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 218. SWITZERLAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 219. SWITZERLAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 220. SWITZERLAND FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 221. TURKEY FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 222. TURKEY FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 223. TURKEY FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 224. TURKEY FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 225. TURKEY FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 226. UNITED ARAB EMIRATES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 227. UNITED ARAB EMIRATES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 228. UNITED ARAB EMIRATES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 229. UNITED ARAB EMIRATES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 230. UNITED ARAB EMIRATES FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 231. UNITED KINGDOM FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
• TABLE 232. UNITED KINGDOM FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 233. UNITED KINGDOM FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 234. UNITED KINGDOM FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 235. UNITED KINGDOM FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 236. FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 237. FIBRODYSPLASIA OSSIFICANS PROGRESSIVA MARKET, FPNV POSITIONING MATRIX, 2023

The Fibrodysplasia Ossificans Progressiva Market was valued at USD 470.46 million in 2023, expected to reach USD 494.59 million in 2024, and is projected to grow at a CAGR of 5.30%, to USD 675.65 million by 2030.

Fibrodysplasia Ossificans Progressiva (FOP) is an ultra-rare, genetic disorder that causes soft tissues to progressively ossify, severely limiting physical mobility and leading to complications in essential bodily functions. The market scope for FOP is highly specialized, given its rarity, but it is critical in terms of medical research and innovation due to the significant impact on patient quality of life. The necessity of developing preventatives and therapeutics is underscored by the lack of effective treatment options currently available, emphasizing both humanitarian and financial incentives. Applications range from novel drug development, gene therapy, and bone biology research to assistive technology and prosthetics that cater specifically to impaired mobility. In terms of end-use, the primary focus is on healthcare providers, research organizations, and pharmaceutical companies, with a secondary market in adaptive equipment manufacturers.

Market growth is driven by increasing government and private funding, advancements in genetics, and rising awareness among healthcare professionals, which stroke collaborations across biotech firms and academic institutions. Potential opportunities exist in leveraging advanced CRISPR technology for gene editing and developing biologics that target the specific pathways involved in heterotopic ossification. Recommendations to seize these opportunities include forming strategic partnerships for resource sharing and investing in early-stage biopharmaceutical ventures. However, limitations like the high cost and time associated with research and clinical trials, small patient populations complicating study feasibility, and regulatory hurdles remain formidable challenges.

Innovation prospects include exploring new molecular pathways, improving diagnostic tools with AI and machine learning, and using patient-driven datasets to enhance personalized medicine approaches. The market is characterized by its dynamic, niche nature-demanding agility and sustained R&D investment. Business growth can be maximized by aligning innovation efforts with patient-centric care models, leveraging emerging technologies, and fostering a collaborative ecosystem among stakeholders, thus keeping pace with the evolving landscape of rare disease treatment solutions.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Fibrodysplasia Ossificans Progressiva Market

The Fibrodysplasia Ossificans Progressiva Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Growing incidence of fibrodysplasia ossificans progressiva diseases
  • Rising awareness among healthcare professionals and the public for rare and genetic diseases
• Market Restraints
  • High cost of development of fibrodysplasia ossificans progressiva treatment
• Market Opportunities
  • Rising research & development activities to develop novel fibrodysplasia ossificans progressiva treatments
  • Availability of government funding and approvals for rare diseases
• Market Challenges
  • Limited awareness for the fibrodysplasia ossificans progressiva

Porter's Five Forces: A Strategic Tool for Navigating the Fibrodysplasia Ossificans Progressiva Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Fibrodysplasia Ossificans Progressiva Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Fibrodysplasia Ossificans Progressiva Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Fibrodysplasia Ossificans Progressiva Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Fibrodysplasia Ossificans Progressiva Market

A detailed market share analysis in the Fibrodysplasia Ossificans Progressiva Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Fibrodysplasia Ossificans Progressiva Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Fibrodysplasia Ossificans Progressiva Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Fibrodysplasia Ossificans Progressiva Market

A strategic analysis of the Fibrodysplasia Ossificans Progressiva Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Fibrodysplasia Ossificans Progressiva Market, highlighting leading vendors and their innovative profiles. These include Abbvie Inc., Accord Healthcare, Inc, Amgen Inc., BioCryst Pharmaceuticals, Inc., bioMerieux S.A., Blueprint Medicines Corporation, Boehringer Ingelheim International GmbH, Daiichi Sankyo Company, Limited, Incyte Corporation, Ipsen Pharma, Merck & Co Inc., Novartis AG, Pfizer, Inc., Regeneron Pharmaceuticals, Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceuticals Industries Ltd., and Thermo Fisher Scientific, Inc..

Market Segmentation & Coverage

This research report categorizes the Fibrodysplasia Ossificans Progressiva Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Offering, market is studied across Drug Type and Treatment. The Drug Type is further studied across Anti-inflammatory Medications, Bisphosphonates, Corticosteroids, and Palovarotene. The Treatment is further studied across Medication, Occupational Therapy, and Surgery.
• Based on Route of Administration, market is studied across Oral, Parenteral, and Topical.
• Based on End-User, market is studied across Hospitals, Research Institutes, and Specialty Clinics.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing incidence of fibrodysplasia ossificans progressiva diseases
    • 5.1.1.2. Rising awareness among healthcare professionals and the public for rare and genetic diseases
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of development of fibrodysplasia ossificans progressiva treatment
  • 5.1.3. Opportunities
    • 5.1.3.1. Rising research & development activities to develop novel fibrodysplasia ossificans progressiva treatments
    • 5.1.3.2. Availability of government funding and approvals for rare diseases
  • 5.1.4. Challenges
    • 5.1.4.1. Limited awareness for the fibrodysplasia ossificans progressiva
• 5.2. Market Segmentation Analysis
  • 5.2.1. Offering: Rising need for palovarotene for reducing the progression of heterotopic ossification in FOP
  • 5.2.2. End-User: High usage of fibrodysplasia ossificans progressiva drugs in hospitals for diagnosis, treatment, and ongoing management of FOP
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Fibrodysplasia Ossificans Progressiva Market, by Offering

• 6.1. Introduction
• 6.2. Drug Type
  • 6.2.1. Anti-inflammatory Medications
  • 6.2.2. Bisphosphonates
  • 6.2.3. Corticosteroids
  • 6.2.4. Palovarotene
• 6.3. Treatment
  • 6.3.1. Medication
  • 6.3.2. Occupational Therapy
  • 6.3.3. Surgery

7. Fibrodysplasia Ossificans Progressiva Market, by Route of Administration

• 7.1. Introduction
• 7.2. Oral
• 7.3. Parenteral
• 7.4. Topical

8. Fibrodysplasia Ossificans Progressiva Market, by End-User

• 8.1. Introduction
• 8.2. Hospitals
• 8.3. Research Institutes
• 8.4. Specialty Clinics

9. Americas Fibrodysplasia Ossificans Progressiva Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Fibrodysplasia Ossificans Progressiva Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Fibrodysplasia Ossificans Progressiva Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. FDA Approves Ipsen Fibrodysplasia Ossificans Progressiva Treatment
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbvie Inc.
• 2. Accord Healthcare, Inc
• 3. Amgen Inc.
• 4. BioCryst Pharmaceuticals, Inc.
• 5. bioMerieux S.A.
• 6. Blueprint Medicines Corporation
• 7. Boehringer Ingelheim International GmbH
• 8. Daiichi Sankyo Company, Limited
• 9. Incyte Corporation
• 10. Ipsen Pharma
• 11. Merck & Co Inc.
• 12. Novartis AG
• 13. Pfizer, Inc.
• 14. Regeneron Pharmaceuticals, Inc.
• 15. Sun Pharmaceutical Industries Ltd.
• 16. Teva Pharmaceuticals Industries Ltd.
• 17. Thermo Fisher Scientific, Inc.